Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 19/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10082912 | 0.94 | MCHR1 (0.74) | MCHR1KCNH2 | |
| SCHEMBL10083235 | 0.91 | MCHR1 (0.98) | MCHR1KCNH2 | |
| SCHEMBL10083267 | 0.91 | MCHR1 (1.00) | MCHR1KCNH2 | |
| SCHEMBL10083237 | 0.90 | MCHR1 (1.00) | MCHR1KCNH2 | |
| SCHEMBL10083238 | 0.90 | MCHR1 (1.00) | MCHR1KCNH2 | |
| SCHEMBL10083233 | 0.88 | MCHR1 (1.00) | MCHR1KCNH2CCR3 | |
| SCHEMBL10083271 | 0.88 | MCHR1 (1.00) | MCHR1KCNH2 | |
| SCHEMBL10083272 | 0.88 | MCHR1 (1.00) | MCHR1KCNH2 | |
| SCHEMBL10082919 | 0.85 | MCHR1 (0.80) | MCHR1KCNH2 | |
| SCHEMBL10082906 | 0.85 | MCHR1 (0.86) | MCHR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552199-B2 | Substituted indanes, method for the production thereof, and use thereof as drugs | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-8552199-B2 | Substituted indanes, method for the production thereof, and use thereof as drugs | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-20120022039-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2012-01-26 | — | — | US | disclosed |
| US-20120022039-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2012-01-26 | — | — | US | disclosed |
| WO-2010092154-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022039-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | MCHR1, MCHR2, IDO1 | MCHR1 1/4885KCNH2 717/4885CCR3 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.